Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 20 de 367
Filtrar
1.
Chem Pharm Bull (Tokyo) ; 71(1): 74-77, 2023.
Artículo en Inglés | MEDLINE | ID: mdl-36596515

RESUMEN

Propan-1,3-diol (PD) and propan-1,2-diol (propylene glycol, PG) are very similar compounds because their structures, safety data, and anti-microbial activities are almost the same. Actually, both compounds are made up of three carbon atoms and two hydroxyl groups. Regarding their safety, they do not have serious hazard data for animals, and LD50 values (in rats) of both are similar. As for the anti-microbial activity, minimum inhibitory concentration (MIC) values of both PD and PG are approximately 10% (v/v). In this study, we used the preservatives-effectiveness test (PET) to evaluate the anti-microbial activities of PD and PG, because both compounds are used in cosmetics as preservatives. The results indicated that PD was more effective as an anti-microbial agent compared with PG, and the effect of PD was marked against Escherichia coli and Pseudomonas aeruginosa. Scanning electron microscopy (SEM) images showed that the membrane of Escherichia coli was injured by PD and PG, but the damage by PD was more marked. The damage of the cell membrane may be the cause of high anti-microbial activity of PD in PET. These results suggest that PD has greater potential as a preservative, and PD should be recommended as an additive for food and medicine.


Asunto(s)
Antiinfecciosos , Propilenglicol , Animales , Ratas , Antiinfecciosos/farmacología , Escherichia coli , Pruebas de Sensibilidad Microbiana , Fenilpropanolamina/farmacología , Conservadores Farmacéuticos/farmacología , Propilenglicol/farmacología
2.
Naunyn Schmiedebergs Arch Pharmacol ; 396(2): 275-287, 2023 02.
Artículo en Inglés | MEDLINE | ID: mdl-36319858

RESUMEN

The use of recreational drugs like ephedrine, norephedrine, 3,4-methylenedioxymethamphetamine (MDMA), and mescaline can lead to intoxication and, at worst, to death. One reason for a fatal course of intoxication with these drugs might lie in cardiac arrhythmias. To the best of our knowledge, their inotropic effects have not yet been studied in isolated human cardiac preparations. Therefore, we measured inotropic effects of the hallucinogenic drugs ephedrine, norephedrine, mescaline, and MDMA in isolated mouse left atrial (mLA) and right atrial (mRA) preparations as well as in human right atrial (hRA) preparations obtained during cardiac surgery. Under these experimental conditions, ephedrine, norephedrine, and MDMA increased force of contraction (mLA, hRA) and beating rate (mRA) in a time- and concentration-dependent way, starting at 1-3 µM but these drugs were less effective than isoprenaline. Mescaline alone or in the presence of phosphodiesterase inhibitors did not increase force in mLA or hRA. The positive inotropic effects of ephedrine, norephedrine, or MDMA were accompanied by increases in the rate of tension and relaxation and by shortening of time of relaxation and, moreover, by an augmented phosphorylation state of the inhibitory subunit of troponin in hRA. All effects were greatly attenuated by cocaine (10 µM) or propranolol (10 µM) treatment. In summary, the hallucinogenic drugs ephedrine, norephedrine, and MDMA, but not mescaline, increased force of contraction and increased protein phosphorylation presumably, in part, by a release of noradrenaline in isolated human atrial preparations and thus can be regarded as indirect sympathomimetic drugs in the human atrium.


Asunto(s)
Fibrilación Atrial , Alucinógenos , N-Metil-3,4-metilenodioxianfetamina , Humanos , Ratones , Animales , N-Metil-3,4-metilenodioxianfetamina/toxicidad , Mescalina/farmacología , Alucinógenos/toxicidad , Efedrina/farmacología , Fenilpropanolamina/farmacología , Atrios Cardíacos , Contracción Miocárdica
3.
J Enzyme Inhib Med Chem ; 36(1): 218-237, 2021 Dec.
Artículo en Inglés | MEDLINE | ID: mdl-33357002

RESUMEN

A set of quinazolinones synthesized by the aid of L-norephedrine was assembled to generate novel analogues as potential anticancer and radiosensitizing agents. The new compounds were evaluated for their cytotoxic activity against MDA-MB-231, MCF-7, HepG-2, HCT-116 cancer cell lines and EGFR inhibitory activity. The most active compounds 5 and 6 were screened against MCF-10A normal cell line and displayed lower toxic effects. They proved their relative safety with high selectivity towards MDA-MB-231 breast cancer cell line. Measurement of the radiosensitizing activity for 5 and 6 revealed that they could sensitize the tumour cells after being exposed to a single dose of 8 Gy gamma radiation. Compound 5 was able to induce apoptosis and arrest the cell cycle at the G2-M phase. Molecular docking of 5 and 6 in the active site of EGFR was performed to gain insight into the binding interactions with the key amino acids.


Asunto(s)
Inhibidores Enzimáticos/síntesis química , Fenilpropanolamina/química , Quinazolinonas/síntesis química , Fármacos Sensibilizantes a Radiaciones/síntesis química , Apoptosis/efectos de los fármacos , Apoptosis/efectos de la radiación , Sitios de Unión , Línea Celular , Proliferación Celular/efectos de los fármacos , Proliferación Celular/efectos de la radiación , Inhibidores Enzimáticos/metabolismo , Inhibidores Enzimáticos/farmacología , Células Epiteliales/citología , Células Epiteliales/efectos de los fármacos , Células Epiteliales/efectos de la radiación , Receptores ErbB/antagonistas & inhibidores , Receptores ErbB/química , Receptores ErbB/metabolismo , Rayos gamma , Células HCT116 , Células Hep G2 , Humanos , Concentración 50 Inhibidora , Células MCF-7 , Simulación del Acoplamiento Molecular , Fenilpropanolamina/metabolismo , Fenilpropanolamina/farmacología , Unión Proteica , Conformación Proteica en Hélice alfa , Conformación Proteica en Lámina beta , Dominios y Motivos de Interacción de Proteínas , Quinazolinonas/metabolismo , Quinazolinonas/farmacología , Fármacos Sensibilizantes a Radiaciones/metabolismo , Fármacos Sensibilizantes a Radiaciones/farmacología , Estereoisomerismo , Relación Estructura-Actividad
4.
Brain Res ; 1748: 147098, 2020 12 01.
Artículo en Inglés | MEDLINE | ID: mdl-32896521

RESUMEN

For over 50 years, the sympathomimetic phenylpropanolamine (PPA; ±-norephedrine) was a primary active ingredient in over-the-counter nasal decongestants for both children and adults and continues to be prevalent in the vast majority of countries today. Previously, we reported that juvenile PPA exposure alters the developmental trajectory of catecholamine and amino acid neurotransmitter systems in the nucleus accumbens (NAC), impacting the motivational valence of cocaine in later life. The present study employed a combination of in vivo microdialysis and immunoblotting approaches to better understand how juvenile PPA exposure impacts catecholamine and glutamate function within the NAC. For this, C57BL/6J mice were pretreated repeatedly with PPA (0 or 40 mg/kg) during postnatal days 21-33. Starting at 70 days of age, the function and expression of receptors and transporters regulating extracellular dopamine and glutamate were determined. Juvenile PPA pretreatment completely abolished the capacity of selective dopamine and epinephrine reuptake inhibitors to increase NAC levels of both catecholamines, without impacting D2 or α2 receptor regulation of catecholamine release. Juvenile PPA pretreatment facilitated the rise in NAC glutamate elicited by dopamine, norepinephrine and glutamate transporter inhibitors and blunted mGlu2/3 inhibition of glutamate release in this region. These data confirm that juvenile exposure to PPA produces protracted perturbations in the regulation of extracellular catecholamine and glutamate levels within the NAC and further the hypothesis that early exposure to sympathomimetic drugs found in cough, cold and allergy medicines, have long-lasting effects upon neurotransmission within brain regions gating motivation.


Asunto(s)
Catecolaminas/metabolismo , Ácido Glutámico/metabolismo , Núcleo Accumbens/efectos de los fármacos , Fenilpropanolamina/farmacología , Simpatomiméticos/farmacología , Transmisión Sináptica/efectos de los fármacos , Animales , Femenino , Masculino , Ratones , Núcleo Accumbens/metabolismo
5.
Genes Brain Behav ; 16(4): 439-448, 2017 04.
Artículo en Inglés | MEDLINE | ID: mdl-27862969

RESUMEN

Phenylpropanolamine (PPA)-induced appetite control is associated with oxidative stress in the hypothalamus. This study explored whether hypothalamic antioxidants participated in hypothalamic ghrelin system-associated appetite control in PPA-treated rats. Rats were given PPA daily for 4 days, and changes in food intake and the expression of neuropeptide Y (NPY), the cocaine- and amphetamine-regulated transcript (CART), superoxide dismutase, catalase, ghrelin, acyl ghrelin (AG), ghrelin O-acyltransferase (GOAT) and the ghrelin receptor (GHSR1a) were examined and compared. Results showed that both food intake and the expression of NPY and ghrelin/AG/GOAT/GHSR1a decreased in response to PPA treatment with maximum decrease on Day 2 of the treatment. In contrast, the expression of antioxidants and CART increased, with the maximum increase on Day 2, with the expression opposite to that of NPY and ghrelin. A cerebral infusion of either a GHSR1a antagonist or reactive oxygen species scavenger modulated feeding behavior and NPY, CART, antioxidants and ghrelin system expression, showing the involvement of ghrelin signaling and oxidative stress in regulating PPA-mediated appetite control. We suggest that hypothalamic ghrelin signaling system, with the help of antioxidants, may participate in NPY/CART-mediated appetite control in PPA-treated rats.


Asunto(s)
Apetito/efectos de los fármacos , Ghrelina/metabolismo , Hipotálamo/efectos de los fármacos , Estrés Oxidativo/efectos de los fármacos , Fenilpropanolamina/farmacología , Animales , Anorexia/inducido químicamente , Apetito/fisiología , Peso Corporal , Ingestión de Alimentos/efectos de los fármacos , Conducta Alimentaria/efectos de los fármacos , Hipotálamo/metabolismo , Masculino , Neuropéptido Y/metabolismo , Estrés Oxidativo/fisiología , Hormonas Peptídicas/farmacología , Ratas , Ratas Wistar , Especies Reactivas de Oxígeno/metabolismo , Receptores de Ghrelina/antagonistas & inhibidores , Receptores de Ghrelina/metabolismo
6.
Curr Top Behav Neurosci ; 32: 19-47, 2017.
Artículo en Inglés | MEDLINE | ID: mdl-27830576

RESUMEN

Until recently, there was rather little interest in the structure-activity relationships (SARs) of cathinone analogs because so few agents were available and because they represented a relatively minor drug abuse problem. Most of the early SAR was formulated on the basis of behavioral (e.g., locomotor and drug discrimination) studies using rodents. With the emergence on the clandestine market in the last few years of a large number of new cathinone analogs, termed "synthetic cathinones", and the realization that they likely act at dopamine, norepinephrine, and/or serotonin transporters as releasing agents (i.e., as substrates) or reuptake inhibitors (i.e., as transport blockers), it has now become possible to better examine their SAR and even their quantitative SAR (QSAR), in a more effective and systematic manner. An SAR picture is beginning to emerge, and key structural features, such as the nature of the terminal amine, the size of the α-substituent, stereochemistry, and the presence and position of aromatic substituents, are being found to impact action (i.e., as releasing agents or reuptake inhibitors) and transporter selectivity.


Asunto(s)
Alcaloides/farmacología , Anfetaminas/farmacología , Estimulantes del Sistema Nervioso Central/farmacología , Fenilpropanolamina/farmacología , Propiofenonas/farmacología , Trastornos Relacionados con Sustancias , Inhibidores de Captación Adrenérgica/química , Inhibidores de Captación Adrenérgica/farmacología , Alcaloides/química , Anfetaminas/química , Animales , Estimulantes del Sistema Nervioso Central/química , Inhibidores de Captación de Dopamina/química , Inhibidores de Captación de Dopamina/farmacología , Humanos , Fenilpropanolamina/química , Propiofenonas/química , Inhibidores Selectivos de la Recaptación de Serotonina/química , Inhibidores Selectivos de la Recaptación de Serotonina/farmacología , Relación Estructura-Actividad
7.
J Biol Chem ; 291(48): 25050-25065, 2016 Nov 25.
Artículo en Inglés | MEDLINE | ID: mdl-27756839

RESUMEN

Aberrant cellular accumulation of cholesterol is associated with neuronal lysosomal storage disorders such as Niemann-Pick disease Type C (NPC). We have shown previously that l-norephedrine (l-Nor), a sympathomimetic amine, induces necrotic cell death associated with massive cytoplasmic vacuolation in SH-SY5Y human neuroblastoma cells. To reveal the molecular mechanism underling necrotic neuronal cell death caused by l-Nor, we examined alterations in the gene expression profile of cells during l-Nor exposure. DNA microarray analysis revealed that the gene levels for cholesterol transport (LDL receptor and NPC2) as well as cholesterol biosynthesis (mevalonate pathway enzymes) are increased after exposure to 3 mm l-Nor for ∼6 h. Concomitant with this observation, the master transcriptional regulator of cholesterol homeostasis, SREBP-2, is activated by l-Nor. The increase in cholesterol uptake as well as biosynthesis is not accompanied by an increase in cholesterol in the plasma membrane, but rather by aberrant accumulation in cytoplasmic compartments. We also found that cell death by l-Nor can be suppressed by nec-1s, an inhibitor of a regulated form of necrosis, necroptosis. Abrogation of SREBP-2 activation by the small molecule inhibitor betulin or by overexpression of dominant-negative SREBP-2 efficiently reduces cell death by l-Nor. The mobilization of cellular cholesterol in the presence of cyclodextrin also suppresses cell death. These results were also observed in primary culture of striatum neurons. Taken together, our results indicate that the excessive uptake as well as synthesis of cholesterol should underlie neuronal cell death by l-Nor exposure, and suggest a possible link between lysosomal cholesterol storage disorders and the regulated form of necrosis in neuronal cells.


Asunto(s)
Proteínas Portadoras/metabolismo , Colesterol/metabolismo , Glicoproteínas/metabolismo , Neuronas/metabolismo , Receptores de LDL/metabolismo , Proteína 2 de Unión a Elementos Reguladores de Esteroles/metabolismo , Proteínas Portadoras/genética , Muerte Celular/efectos de los fármacos , Muerte Celular/genética , Línea Celular Tumoral , Colesterol/genética , Glicoproteínas/genética , Humanos , Enfermedad de Niemann-Pick Tipo C/genética , Enfermedad de Niemann-Pick Tipo C/metabolismo , Análisis de Secuencia por Matrices de Oligonucleótidos , Fenilpropanolamina/farmacología , Receptores de LDL/genética , Proteína 2 de Unión a Elementos Reguladores de Esteroles/genética , Proteínas de Transporte Vesicular
8.
Bioorg Med Chem Lett ; 25(19): 4232-8, 2015 Oct 01.
Artículo en Inglés | MEDLINE | ID: mdl-26296475

RESUMEN

Antimicrobial agents 4a-g and 5a-g with very good potency were synthesized with 100% ee from phenylpropanolamine (norephedrine) by BF3 catalyzed three components one pot Mannich reaction in good yields. Obtained compounds were characterized using spectral techniques. Antimicrobial study of these compounds revealed a good to very high potential activity against tested microbes when compared to standard antimicrobial drugs streptomycin and ketoconazole. These synthesized compounds exhibited significant minimum inhibitory concentration (MIC) values against Gram positive and Gram negative bacteria. Amongst compound 4b, 4c, 4d, 4e, 5a, and 5e exhibited very high potent MIC values against tested twelve bacteria and three fungi when compared to control. When subjected to molecular docking, in silico studies revealed significant binding energies ranging from -7.06 to -8.90 kcal/mol for all obtained compounds towards target receptor DNA topoisomerase IV and amongst compounds 4b and 4d have shown maximum binding energies 8.70 and 8.90 kcal/mol, respectively.


Asunto(s)
Antibacterianos/farmacología , Bacterias Gramnegativas/efectos de los fármacos , Bacterias Grampositivas/efectos de los fármacos , Bases de Mannich/química , Bases de Mannich/farmacología , Simulación del Acoplamiento Molecular , Fenilpropanolamina/farmacología , Antibacterianos/síntesis química , Antibacterianos/química , Boranos , Catálisis , Relación Dosis-Respuesta a Droga , Pruebas de Sensibilidad Microbiana , Estructura Molecular , Fenilpropanolamina/síntesis química , Fenilpropanolamina/química , Relación Estructura-Actividad
9.
Int Rev Neurobiol ; 120: 235-55, 2015.
Artículo en Inglés | MEDLINE | ID: mdl-26070760

RESUMEN

Khat, Catha edulis Forsk, is among the most widely used plant-based psychoactive substance in the world. Grown in Eastern Africa, Horn of Africa, and southwestern part of the Arabian Peninsula, its fresh young leaves and twigs are used daily by over 20 million people for the psychostimulatory effects it produces in the user, a practice deeply rooted in the history, tradition, and culture of the indigenous population. Once hardly known outside the regions where it is grown and used, khat use has now spread to other countries. This review will cover the, phytochemistry, pharmacokinetics of the active ingredients-cathinone, cathine, norephedrine, neurochemistry, effects on cognitive and executive functions as well as its ability to produce dependency in the user. Whether it is an innocuous cultural practice or a drug of abuse is debatable as the preclinical and clinical data needed to arrive at an authoritative conclusion is lacking.


Asunto(s)
Alcaloides/efectos adversos , Catha/efectos adversos , Fenilpropanolamina/efectos adversos , Trastornos Relacionados con Sustancias/psicología , Alcaloides/farmacocinética , Alcaloides/farmacología , Encéfalo/efectos de los fármacos , Desarrollo Infantil/efectos de los fármacos , Cognición/efectos de los fármacos , Humanos , Lactante , Fenilpropanolamina/farmacocinética , Fenilpropanolamina/farmacología , Psicosis Inducidas por Sustancias
10.
Aging Ment Health ; 19(3): 217-23, 2015.
Artículo en Inglés | MEDLINE | ID: mdl-25555041

RESUMEN

OBJECTIVES: Incidences of overactive bladder (OAB) and cognitive dysfunction increase with aging. Treatment of OAB with antimuscarinic agents may result in cognitive decline, especially in patients with Alzheimer's disease (AD). The aim of this study is to evaluate the effect of antimuscarinic treatment on cognitive functions, depression, and quality of life (QOL) of patients with OAB. METHODS: This non-interventional prospective observational study was conducted in a geriatric medicine outpatient clinic. Overall, 168 OAB patients were enrolled. Patients were followed up in five groups: oxybutynin, darifenacin, tolterodine, trospium, and control groups. Follow-up visits were done at second, third, and sixth months. Comprehensive geriatric assessment, cognitive and mood assessment, QOL scales (IIQ-7, UDI-6) were performed. RESULTS: Mean age of the patients was 73.5 ± 6.1. Of the 168 patients, 92.3% were female, 83.3% benefited from the treatment, and 37.1% discontinued the medication. Discontinuation rate and frequency of side effects were more frequent in the oxybutynin group. Mini Mental State Examination scores did not decline after treatment, even in AD patients. Geriatric Depression Scale scores, Activities of Daily Living scores, and QOL scores significantly improved after treatment. CONCLUSION: Antimuscarinic agents are effective in OAB treatment. They have a positive impact on daily life activities, depression, and QOL indices. Furthermore, they do not have a negative effect on cognitive function in older adults with or without AD.


Asunto(s)
Trastornos del Conocimiento/inducido químicamente , Depresión/tratamiento farmacológico , Antagonistas Muscarínicos/farmacología , Calidad de Vida/psicología , Vejiga Urinaria Hiperactiva/tratamiento farmacológico , Actividades Cotidianas/psicología , Anciano , Anciano de 80 o más Años , Compuestos de Bencidrilo/efectos adversos , Compuestos de Bencidrilo/farmacología , Bencilatos/efectos adversos , Bencilatos/farmacología , Benzofuranos/efectos adversos , Benzofuranos/farmacología , Cresoles/efectos adversos , Cresoles/farmacología , Femenino , Estudios de Seguimiento , Evaluación Geriátrica , Humanos , Masculino , Ácidos Mandélicos/efectos adversos , Ácidos Mandélicos/farmacología , Antagonistas Muscarínicos/efectos adversos , Nortropanos/efectos adversos , Nortropanos/farmacología , Fenilpropanolamina/efectos adversos , Fenilpropanolamina/farmacología , Pirrolidinas/efectos adversos , Pirrolidinas/farmacología , Tartrato de Tolterodina , Resultado del Tratamiento
11.
Can Vet J ; 56(1): 39-43, 2015 Jan.
Artículo en Inglés | MEDLINE | ID: mdl-25565712

RESUMEN

This prospective, cross-over, blinded study evaluated the effect of various doses of phenylpropanolamine (PPA) on blood pressure in dogs. Dogs were randomized to receive a placebo or 1 of 3 dosages of immediate release PPA, q12h for 7 days [1 mg/kg body weight (BW), 2 mg/kg BW, or 4 mg/kg BW] in a cross-over design. Blood pressure was recorded every 2 h, for 12 h, on days 1 and 7. There were significant increases in systolic, diastolic, and mean blood pressure following administration of PPA at 2 mg/kg BW and 4 mg/kg BW. A significant decrease in heart rate was also noted at all PPA dosages, but not in the placebo. Administration of PPA was associated with a dose response increase in blood pressure. Dosages of up to 2 mg/kg BW should be considered safe in healthy dogs.


Changements de la pression artérielle après des doses progressives de phénylpropanolamine et suggestion d'un protocole de surveillance. Cette étude prospective à l'insu et à plan d'étude croisée a évalué l'effet de diverses doses de phénylpropanolamine (PPA) sur la pression artérielle des chiens. Les chiens ont reçu au hasard un placebo ou 1 de 3 doses de PPA à action immédiate, q12h pendant 7 jours (1 mg/kg de poids corporel [PC], 2 mg/kg PC ou 4 mg/kg PC) dans un plan d'étude croisé. La pression artérielle a été consignée toutes les 2 h, pendant 12 h, aux jours 1 et 7. Il n'y a pas eu de hausses significatives de la pression artérielle systolique et diastolique ni de la pression artérielle moyenne après l'administration de PPA à 2 mg/kg PC et à 4 mg/kg PC. Une baisse significative de la fréquence cardiaque a aussi été notée dans toutes les doses de PPA, mais non avec le placebo. L'administration de PPA a été associée à une hausse de la pression artérielle en fonction de la dose. Des doses jusqu'à 2 mg/kg PC devraient être considérées sûres chez des chiens en santé.(Traduit par Isabelle Vallières).


Asunto(s)
Agonistas alfa-Adrenérgicos/farmacología , Monitoreo Ambulatorio de la Presión Arterial/veterinaria , Presión Sanguínea/efectos de los fármacos , Perros/fisiología , Fenilpropanolamina/farmacología , Agonistas alfa-Adrenérgicos/administración & dosificación , Animales , Estudios Cruzados , Relación Dosis-Respuesta a Droga , Femenino , Frecuencia Cardíaca/efectos de los fármacos , Masculino , Fenilpropanolamina/administración & dosificación
12.
Arch Toxicol ; 89(1): 87-100, 2015 Jan.
Artículo en Inglés | MEDLINE | ID: mdl-24792324

RESUMEN

It has been reported that the redox sensing system in the hypothalamus participates in fuel metabolism and that endogenous antioxidants contribute to the regulation of phenylpropanolamine (PPA), an anorectic drug-induced appetite suppression. We explored whether the signal transducer and activator of transcription-3 (STAT3) is involved in PPA's action. Rats were given PPA once a day for 4 days. Changes in endogenous antioxidants, Janus kinase-2 (JAK2), STAT3, neuropeptide Y (NPY), and proopiomelanocortin (POMC), levels during PPA treatment were assessed and compared. Feeding, body weight, and NPY decreased with the biggest reduction on Day 2 during PPA treatment. Antioxidants, JAK2, pSTAT3, POMC expression, and STAT3/DNA-binding activity increased and were expressed in a pattern opposite to NPY expression. Moreover, cerebral STAT3 knockdown modified PPA-induced anorexia and antioxidants, POMC, and NPY expression. superoxide dismutase immunoreactivity in the hypothalamus increased and the inhibition of hypothalamic reactive oxygen species (ROS) production reversed antioxidants, STAT3, POMC, and NPY expression. It is suggested that hypothalamic JAK2-STAT3 participates in regulating antioxidants-mediated appetite control. This result may further the understanding of ROS-involved appetite control.


Asunto(s)
Antioxidantes/metabolismo , Depresores del Apetito/farmacología , Hipotálamo/efectos de los fármacos , Estrés Oxidativo/efectos de los fármacos , Fenilpropanolamina/farmacología , Factor de Transcripción STAT3/genética , Animales , Western Blotting , Peso Corporal/efectos de los fármacos , Ingestión de Alimentos/efectos de los fármacos , Electroforesis en Gel de Agar , Hipotálamo/metabolismo , Janus Quinasa 2/metabolismo , Masculino , Neuropéptido Y/metabolismo , Proopiomelanocortina/metabolismo , Ratas Wistar , Especies Reactivas de Oxígeno/metabolismo , Reacción en Cadena de la Polimerasa de Transcriptasa Inversa
13.
Int J Pharm ; 471(1-2): 322-31, 2014 Aug 25.
Artículo en Inglés | MEDLINE | ID: mdl-24882035

RESUMEN

A transparent film-forming hydrogel formulation for tolterodine was developed using ternary phase diagram and Box-Behnken design (BBD). Carbopol 980 (neutralized by triethanolamine), hydroxypropyl cellulose (HPC), hydroxypropyl methyl cellulose (HPMC) and Tween 80 were used as matrices. Solvent was the mixture of water and ethyl alcohol. The measured 24 h cumulative drug release rate (86.02%) was consistent with the predicted value (85.42%) in mice. Steady-state flux (J) of tolterodine in optimized formulation across rat full skin, epidermal, dermis and subcutaneous tissue were 15.83, 18.55, 37.15 and 81.82 µg cm(-2) h(-1), respectively. Fourier transform infrared spectroscopy (FTIR) and differential scanning calorimetry (DSC) results suggested that the hydrogels could impact lipid status in SC, which was consistent with Ea (8.638 kcal/mol) of tolterodine from optimized formulation in rats. In the pharmacokinetic studies, sustained-release over 24 h and absolute bioavailability of the hydrogels (24.53%) was higher than tolterodine tablets (15.16%) in rats. The hydrogels were suitable for systemic administration of tolterodine for the treatment of overactive bladder.


Asunto(s)
Compuestos de Bencidrilo/administración & dosificación , Cresoles/administración & dosificación , Portadores de Fármacos/química , Hidrogeles/química , Antagonistas Muscarínicos/administración & dosificación , Fenilpropanolamina/administración & dosificación , Absorción Cutánea/efectos de los fármacos , Piel/efectos de los fármacos , Administración Cutánea , Animales , Compuestos de Bencidrilo/farmacocinética , Compuestos de Bencidrilo/farmacología , Cresoles/farmacocinética , Cresoles/farmacología , Composición de Medicamentos , Diseño de Fármacos , Liberación de Fármacos , Femenino , Ratones Endogámicos , Antagonistas Muscarínicos/farmacocinética , Antagonistas Muscarínicos/farmacología , Transición de Fase , Fenilpropanolamina/farmacocinética , Fenilpropanolamina/farmacología , Ratas Sprague-Dawley , Piel/metabolismo , Espectroscopía Infrarroja por Transformada de Fourier , Propiedades de Superficie , Distribución Tisular , Tartrato de Tolterodina , Vejiga Urinaria Hiperactiva/tratamiento farmacológico
14.
Mol Med Rep ; 10(2): 670-6, 2014 Aug.
Artículo en Inglés | MEDLINE | ID: mdl-24859757

RESUMEN

The aim of the present study was to use an animal model of interstitial cystitis (IC) in order to investigate the histology and function of the bladder, with a particular focus on mast cell degranulation and response to detrusor overactivity (DO) to tolterodine. A total of 18 female Sprague­Dawley rats were used. In 12 rats, lipopolysaccharide (LPS) was intravesically instilled following the induction of IC by protamine sulfate (PS) and six rats were subjected to sham instillations. Following 1 month, cystometry was performed. The effects of tolterodine were tested in half of the animals with IC. All rats in the IC group demonstrated DO during the filling phase and no significant changes in the frequency or pressure compared with that following tolterodine injection were identified. Histological examination revealed a significant increase in the total number of infiltrated mast cells in IC rats compared with that in the sham rats (P<0.05). Degranulated mast cells were evident in 80% of rats with IC; however, they were not apparent in the sham rats. Urinary bladder inflammation, similar to that in human IC in terms of degranulated mast cells and bladder function, was induced in rats. The animal model used in the present study provided insight into the pathophysiological mechanisms underlying the ineffectiveness of anticholinergics in patients with overlapping IC and overactive bladder (OAB).


Asunto(s)
Cistitis Intersticial/patología , Mastocitos/metabolismo , Vejiga Urinaria/efectos de los fármacos , Agentes Urológicos/farmacología , Animales , Compuestos de Bencidrilo/farmacología , Enfermedad Crónica , Cresoles/farmacología , Cistitis Intersticial/inducido químicamente , Modelos Animales de Enfermedad , Femenino , Lipopolisacáridos/toxicidad , Mastocitos/citología , Mastocitos/efectos de los fármacos , Fenilpropanolamina/farmacología , Protaminas/toxicidad , Ratas , Ratas Sprague-Dawley , Tartrato de Tolterodina , Vejiga Urinaria/patología , Vejiga Urinaria/fisiología , Urodinámica
15.
Chem Biol Interact ; 208: 64-76, 2014 Feb 05.
Artículo en Inglés | MEDLINE | ID: mdl-24316275

RESUMEN

In the past decade, a large number of enantiopure drugs were introduced to clinical practice, since improved therapeutic effects were demonstrated for one of the enantiomers from originally racemic drug. While the therapeutic effects and safety of enantiopure drugs were tested prior to their approval, various biological enantiospecific activities of these, often "old" drugs, remain to be elucidated. In the current paper, we examined enantiospecific effects of clinically used enantiopure drugs containing one chiral center in the structure (i.e. zopiclone, tamsulosin, tolterodine, modafinil, citalopram) towards aryl hydrocarbon (AhR), glucocorticoid (GR) and pregnane X (PXR) receptors in human reporter cell lines. The cytotoxicity (IC50), agonist (EC50) and antagonist effects (IC50) of R-form, S-form and racemic mixture for each tested drugs were determined and compared in AhR-, GR- and PXR-gene reporter cell lines. Since AhR, GR and PXR are key regulators of drug metabolism, energy metabolism, immunity and play many other physiological functions, the data presented here might be of toxicological significance.


Asunto(s)
Receptores de Hidrocarburo de Aril/metabolismo , Receptores de Glucocorticoides/metabolismo , Receptores de Esteroides/metabolismo , Compuestos de Azabiciclo/química , Compuestos de Azabiciclo/farmacología , Compuestos de Bencidrilo/química , Compuestos de Bencidrilo/farmacología , Línea Celular , Línea Celular Tumoral , Citalopram/química , Citalopram/farmacología , Cresoles/química , Cresoles/farmacología , Genes Reporteros/genética , Células Hep G2 , Humanos , Modafinilo , Fenilpropanolamina/química , Fenilpropanolamina/farmacología , Piperazinas/química , Piperazinas/farmacología , Receptor X de Pregnano , Receptores de Hidrocarburo de Aril/agonistas , Receptores de Hidrocarburo de Aril/antagonistas & inhibidores , Receptores de Glucocorticoides/agonistas , Receptores de Glucocorticoides/antagonistas & inhibidores , Receptores de Esteroides/agonistas , Receptores de Esteroides/antagonistas & inhibidores , Estereoisomerismo , Sulfonamidas/química , Sulfonamidas/farmacología , Tamsulosina , Tartrato de Tolterodina
16.
Neurourol Urodyn ; 33(7): 1110-5, 2014 Sep.
Artículo en Inglés | MEDLINE | ID: mdl-24038213

RESUMEN

AIMS: Studies of overactive bladder (OAB) have shown urothelial/suburothelial changes and increased bladder afferents, while in the brain the frontal micturition area that normally suppresses the bladder is deactivated. It has been unclear whether anticholinergic medication could reverse this suppression. To address this question, we performed a real-time NIRS (near-infrared spectroscopy)-urodynamic study in OAB patients before and after the administration of an anticholinergic agent, tolterodine. METHODS: We recruited 13 OAB patients in our outpatient clinic (9 males, 4 female; mean age 73 years). Before and after the administration of 4 mg/day tolterodine for 3 months, all patients completed the OAB-symptom scale and a NIRS-urodynamics examination. Cerebral changes in the oxy-hemoglobin concentration (oxy-Hb) were sampled. Concentration changes in oxy-Hb were calculated based on a modified Beer-Lambert approach. RESULTS: Tolterodine significantly reduced the OAB patients' nighttime frequency (P < 0.05) and increased their first-sensation volume (290-359 ml, P < 0.01). The number of patients with detrusor overactivity did not lessen significantly (11-9). The real-time NIRS-urodynamic study showed that, during slow bladder filling between start and bladder capacity, tolterodine significantly activated the right frontal micturition area of the OAB patients (P < 0.05). The activation was prominent in Brodmann's area 8, 9, 10 of the prefrontal cortex. CONCLUSIONS: Tolterodine reduced bladder sensation together with a significant activation of the frontal micturition area of OAB patients, particularly Brodmann's area 8, 9, 10 of the right prefrontal cortex. This activation seems to be a secondary phenomenon, since tolterodine does not easily penetrate the blood-brain barrier.


Asunto(s)
Compuestos de Bencidrilo/farmacología , Cresoles/farmacología , Antagonistas Muscarínicos/farmacología , Fenilpropanolamina/farmacología , Corteza Prefrontal/efectos de los fármacos , Vejiga Urinaria Hiperactiva/tratamiento farmacológico , Urodinámica/efectos de los fármacos , Agentes Urológicos/farmacología , Anciano , Anciano de 80 o más Años , Femenino , Humanos , Masculino , Persona de Mediana Edad , Antagonistas Muscarínicos/uso terapéutico , Corteza Prefrontal/fisiopatología , Espectroscopía Infrarroja Corta , Tartrato de Tolterodina , Resultado del Tratamiento , Vejiga Urinaria Hiperactiva/fisiopatología , Urodinámica/fisiología , Agentes Urológicos/uso terapéutico
17.
Naunyn Schmiedebergs Arch Pharmacol ; 386(12): 1095-102, 2013 Dec.
Artículo en Inglés | MEDLINE | ID: mdl-23995257

RESUMEN

The prevalence of overactive bladder (OAB) and Alzheimer's disease (AD) increases with age, and much attention has been paid to the risk of cognitive impairment which may be induced by antimuscarinics used for OAB in patients with AD. Imidafenacin, an antimuscarinic agent for OAB treatment, has been reported not to affect learning in normal animals. However, under the condition in which sensitivity to learning impairment by antimuscarinics is increased, it remains unclear whether imidafenacin still does not impair the learning. Therefore, the influences of imidafenacin on passive avoidance response were investigated in sham-operated and nucleus basalis of Meynert (nbM)-lesioned rats and compared with oxybutynin hydrochloride and tolterodine tartrate. The learning-inhibitory doses of intravenous oxybutynin hydrochloride and tolterodine tartrate were 0.3 and 3 mg/kg in sham-operated rats and 0.1 and 1 mg/kg in nbM-lesioned rats, respectively. Thus, the learning impairments by those antimuscarinics were more sensitive in nbM-lesioned rats than in sham-operated rats. On the other hand, intravenous administration of imidafenacin had no influence on learning in either case of the rats. In normal rats, however, intracerebroventricular administration of imidafenacin impaired learning to the same degree as that of oxybutynin hydrochloride. Thus, the present study suggests that imidafenacin, unlike the other antimuscarinics used, has no significant risk of enhancing learning impairment even in models whose sensitivity to learning impairment by antimuscarinics is commonly increased, probably because of its low brain penetration.


Asunto(s)
Núcleo Basal de Meynert/efectos de los fármacos , Conducta Animal/efectos de los fármacos , Imidazoles/farmacología , Aprendizaje/efectos de los fármacos , Antagonistas Muscarínicos/farmacología , Animales , Núcleo Basal de Meynert/lesiones , Núcleo Basal de Meynert/fisiopatología , Compuestos de Bencidrilo/farmacología , Barrera Hematoencefálica/metabolismo , Permeabilidad Capilar , Cresoles/farmacología , Relación Dosis-Respuesta a Droga , Imidazoles/administración & dosificación , Imidazoles/metabolismo , Imidazoles/toxicidad , Inyecciones Intravenosas , Inyecciones Intraventriculares , Masculino , Ácidos Mandélicos/farmacología , Antagonistas Muscarínicos/administración & dosificación , Antagonistas Muscarínicos/metabolismo , Antagonistas Muscarínicos/toxicidad , Fenilpropanolamina/farmacología , Ratas , Ratas Wistar , Tiempo de Reacción/efectos de los fármacos , Tartrato de Tolterodina
18.
Expert Opin Pharmacother ; 14(14): 1987-91, 2013 Oct.
Artículo en Inglés | MEDLINE | ID: mdl-23885788

RESUMEN

INTRODUCTION: Overactive bladder (OAB) and its resultant urge urinary incontinence (UUI) are significant problems that medically, psychologically and financially affect people. The constellation of symptoms comprising OAB affects ∼ 16% of the adult population and its prevalence increases with aging. The typical class of medications used to treat OAB is antimuscarinics. AREAS COVERED: OAB medications, with a focus on tolterodine for the treatment of UUI are reviewed. A thorough review of English language literature using EMBASE/Medline and PubMed has been performed. EXPERT OPINION: Tolterodine provides a reasonable starting point when treating patients with OAB and UUI. Efficacy and tolerability are generally comparable between tolterodine and other newer antimuscarinics. Tolterodine is a good option as part of the algorithm in the treatment of OAB and UUI.


Asunto(s)
Compuestos de Bencidrilo/uso terapéutico , Cresoles/uso terapéutico , Antagonistas Muscarínicos/uso terapéutico , Fenilpropanolamina/uso terapéutico , Vejiga Urinaria Hiperactiva/tratamiento farmacológico , Incontinencia Urinaria de Urgencia/tratamiento farmacológico , Agentes Urológicos/uso terapéutico , Compuestos de Bencidrilo/farmacología , Cresoles/farmacología , Humanos , Antagonistas Muscarínicos/farmacología , Fenilpropanolamina/farmacología , Tartrato de Tolterodina , Resultado del Tratamiento , Agentes Urológicos/farmacología
19.
Int J Pharm ; 454(1): 532-8, 2013 Sep 15.
Artículo en Inglés | MEDLINE | ID: mdl-23891744

RESUMEN

In this study, transdermal gel formulations for tolterodine were developed to investigate the effects of gel matrix and chemical enhancers on drug skin permeation from tolterodine hydrogels. In vitro permeation studies of tolterodine through excised mouse skin were carried out using Franz-type diffusion cells. In the optimum gel formulation, Carbopol 940 was selected as the gel matrix. Compared to gels without enhancer, tolterodine hydrogels with N-methyl pyrrolidone (NMP) showed significant enhancing effect on transdermal permeation of tolterodine (p<0.05). The results of in vitro percutaneous delivery experiment showed that the relationship of the steady accumulative percutaneous amount (Q, µg cm(-2)) of tolterodine hydrogels and time was Q4-12h=770.19t(1/2)-966.99. Tolterodine permeated at the steady-state speed of 770.19 µg cm(-2)h(-1) and its release coincided with Higuchi Equation. The pharmacokinetic properties of the optimized tolterodine formulation were studied in rabbits. The absolute bioavailability of tolterodine was 11.47%. Since the absence of hepatic first-pass metabolism, only a single active compound-tolterodine was detected in the plasma. A skin irritation study was also carried out on rabbits, and the results showed tolterodine hydrogels had no skin irritation. In the pharmacodynamic study, the significant effects of tolterodine hydrogels on the inhibition of pilocarpine-induced rat urinary bladder contraction were last to 12h, indicating that tolterodine hydrogels could produce prolonged pharmacological responses. In conclusion, tolterodine hydrogels were formulated successfully using Carbopol 940 and NMP and these results helped in finding the optimum formulation for percutaneous drug release. It is quite evident that tolterodine hydrogels may offer a possibility to avoid the first-pass effect, resulting in a single active compound of tolterodine in plasma, which may profit on the patient under the dose control and the reduction of potential adverse effect from two active compounds in the body.


Asunto(s)
Resinas Acrílicas/química , Compuestos de Bencidrilo/farmacología , Cresoles/farmacología , Portadores de Fármacos , Antagonistas Muscarínicos/farmacología , Fenilpropanolamina/farmacología , Pirrolidinonas/farmacología , Vejiga Urinaria Hiperactiva/tratamiento farmacológico , Agentes Urológicos/farmacología , Resinas Acrílicas/toxicidad , Administración Cutánea , Animales , Compuestos de Bencidrilo/administración & dosificación , Compuestos de Bencidrilo/química , Compuestos de Bencidrilo/farmacocinética , Compuestos de Bencidrilo/toxicidad , Disponibilidad Biológica , Biotransformación , Química Farmacéutica , Cresoles/administración & dosificación , Cresoles/química , Cresoles/farmacocinética , Cresoles/toxicidad , Hidrogeles , Inyecciones Intravenosas , Masculino , Ratones , Modelos Biológicos , Antagonistas Muscarínicos/administración & dosificación , Antagonistas Muscarínicos/química , Antagonistas Muscarínicos/farmacocinética , Antagonistas Muscarínicos/toxicidad , Contracción Muscular/efectos de los fármacos , Permeabilidad , Fenilpropanolamina/administración & dosificación , Fenilpropanolamina/química , Fenilpropanolamina/farmacocinética , Fenilpropanolamina/toxicidad , Pirrolidinonas/administración & dosificación , Pirrolidinonas/química , Conejos , Ratas , Piel/efectos de los fármacos , Piel/metabolismo , Absorción Cutánea/efectos de los fármacos , Pruebas de Irritación de la Piel , Tecnología Farmacéutica/métodos , Tartrato de Tolterodina , Vejiga Urinaria/efectos de los fármacos , Vejiga Urinaria Hiperactiva/fisiopatología , Agentes Urológicos/administración & dosificación , Agentes Urológicos/química , Agentes Urológicos/farmacocinética , Agentes Urológicos/toxicidad
20.
BMC Pharmacol Toxicol ; 14: 35, 2013 Jul 11.
Artículo en Inglés | MEDLINE | ID: mdl-23845085

RESUMEN

BACKGROUND: Amphetamine and amphetamine derivatives are suggested to induce an immunosuppressive effect. However, knowledge of how amphetamines modulate intracellular signaling pathways in cells of the immune system is limited. We have studied phosphorylation of signal transduction proteins (Akt, CREB, ERK1/2, NF-κB, c-Cbl, STAT1/3/5/6) and stress sensors (p38 MAPK, p53) in human leukocyte subsets following in vitro treatment with the natural amphetamine cathinone, the cathinone derivatives cathine and norephedrine, in comparison with a defined extract of the psychostimulating herb khat (Catha edulis Forsk.). Intracellular protein modifications in single cells were studied using immunostaining and flow cytometry, cell viability was determined by Annexin V-FITC/Propidium Iodide staining, and T-lymphocyte proliferation was measured by (3)H-thymidine incorporation. RESULTS: Cathinone, cathine and norephedrine generally reduced post-translational modifications of intracellular signal transducers in T-lymphocytes, B-lymphocytes, natural killer cells and monocytes, most prominently affecting c-Cbl (pTyr700), ERK1/2 (p-Thr202/p-Tyr204), p38 MAPK (p-Thr180/p-Tyr182) and p53 (both total p53 protein and p-Ser15). In contrast, the botanical khat-extract induced protein phosphorylation of STAT1 (p-Tyr701), STAT6 (p-Tyr641), c-Cbl (pTyr700), ERK1/2 (p-Thr202/p-Tyr204), NF-κB (p-Ser529), Akt (p-Ser473), p38 MAPK (p-Thr180/p-Tyr182), p53 (Ser15) as well as total p53 protein. Cathinone, cathine and norephedrine resulted in unique signaling profiles, with B-lymphocytes and natural killer cells more responsive compared to T-lymphocytes and monocytes. Treatment with norephedrine resulted in significantly increased T-lymphocyte proliferation, whereas khat-extract reduced proliferation and induced cell death. CONCLUSIONS: Single-cell signal transduction analyses of leukocytes distinctively discriminated between stimulation with cathinone and the structurally similar derivatives cathine and norephedrine. Cathinone, cathine and norephedrine reduced phosphorylation of c-Cbl, ERK1/2, p38 MAPK and p53(Ser15), and norephedrine induced T-lymphocyte proliferation. Khat-extract induced protein phosphorylation of signal transducers, p38 MAPK and p53, followed by reduced cell proliferation and cell death. This study suggests that protein modification-specific single-cell analysis of immune cells could unravel pharmacologic effects of amphetamines and amphetamine-like agents, and further could represent a valuable tool in elucidation of mechanism(s) of action of complex botanical extracts.


Asunto(s)
Alcaloides/farmacología , Catha , Leucocitos Mononucleares/efectos de los fármacos , Fenilpropanolamina/farmacología , Extractos Vegetales/farmacología , Proliferación Celular/efectos de los fármacos , Supervivencia Celular/efectos de los fármacos , Células Cultivadas , Humanos , Leucocitos Mononucleares/citología , Leucocitos Mononucleares/metabolismo , Transducción de Señal/efectos de los fármacos
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA
...